Skip to main content

Table 3 UVA of sites of metastases with clinical outcome

From: Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy

Site of Metastasis

OS

PFS

CB

HR (CI)

p-value

HR (CI)

p-value

OR (CI)

p-value

No lymph node metastases (n = 32)

1.42 (0.79–2.54)

0.244

1.16 (0.74–1.83)

0.524

0.73 (0.31–1.76)

0.486

Lymph node metastases (n = 58)

–

–

–

–

–

–

No bone metastases (n = 66)

0.61 (0.32–1.17)

0.135

0.80 (0.48–1.32)

0.376

2.00 (0.75–5.31)

0.164

Bone metastases (n = 24)

–

–

–

–

–

–

No liver metastases (n = 50)

0.42 (0.23–0.78)

0.006*

0.60 (0.39–0.93)

0.024*

2.64 (1.11–6.28)

0.028*

Liver metastases (n = 40)

–

–

–

–

–

–

No brain metastases (n = 82)

0.69 (0.29–1.64)

0.406

0.86 (0.40–1.88)

0.712

1.44 (0.32–6.42)

0.633

Brain metastases

–

–

–

–

–

–

No lung (n = 53)

1.02 (0.57–1.82)

0.944

1.20 (0.76–1.87)

0.433

1.17 (0.50–2.73)

0.713

Lung metastases (n = 37)

–

–

–

–

–

–

  1. UVA Univariate analysis, OS overall survival, PFS progression-free survival, CB clinical benefit, HR Hazard Ratio, CI Confidence Interval, OR Odds Ratio
  2. *statistical significance at alpha < 0.05